Instrument Inactif

Communiqués RXi Pharmaceuticals Corp Nasdaq

Actions

US74979C5013

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging	18/06	NE
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762	29/05	AQ
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762	28/05	NE
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)	23/05	NE
Phio Pharmaceuticals Secures New Investor	17/05	AQ
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)	16/05	AQ
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study	15/05	AQ
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update	09/05	GL
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)	30/04	AQ
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells	22/04	AQ
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)	16/04	AQ
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)	11/04	AQ
National Spotlight Features Phio’s Innovative RNAi Technology Platform	03/04	AQ
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update	02/04	GL
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	21/03	AQ
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research	13/03	AQ
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders	06/03	AQ
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	31/01	AQ
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds	07/12	AQ
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	09/11	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués RXi Pharmaceuticals Corp Nasdaq

Actions

US74979C5013

Communiqués

Filtres